In-house biomanufacturing is costly. Besides the heavy infrastructure investment required, the need to efficiently manage talent, capacity, financial resources and quality often encourages pharma companies to consider outsourcing as an alternative. However, despite the growing number of CMO and CDMO within China, the availability of CMO providing high quality yet affordable services is lagging way behind the amount of demand within the market. What are the key considerations for pharma companies to take note when deciding their outsourcing partner? How can industry work together to capitalise on the size and potential of China’s biopharmaceutical industry to become a world biopharmaceutical leader?
At BioPharma Asia Convention 2017, we invite experts to address the latest trends and development in various aspect of biopharmaceutical value chain in Asia. Among the discussions, we explore strategies for managing an evolving biologics portfolio, quality management, continuous manufacturing and more. One of the early confirmed speakers is Dr Claudia Lin, General Manager of Jiangsu Alphamab from China who will address the topic of “In-house manufacturing or outsourcing: Balancing the benefits and costs when selecting CMO in Asia”. Recognised for her experience working in both international and local pharma in the US and China, Claudia will share with you her expertise in managing CMOs and an overview of QbD in Asia’s biomanufacturing landscape.
Click here for a list of global biotech CMO by location (courtesy of BiopharmaGuy)
BioPharma Asia, taking place in Singapore from 22-23 March 2017 in Singapore, attracts over 1500 attendees annually. Topics from early R&D, clinical research, biomanufacturing, supply chain, market access, medical affairs and more are discussed extensively in the 3-day conference. Book now to join us.